Literature DB >> 1546136

Tyramine content of preserved and fermented foods or condiments of Far Eastern cuisine.

M Da Prada1, G Zürcher.   

Abstract

The tyramine content of foodstuffs typical of the Far East was analysed: the items included fermented food and condiments as well as seven menus from different Far Eastern restaurants. The results of the present analysis extend to Far Eastern foods our previous conclusion that no severe dietary restrictions are needed in patients treated with moclobemide, a novel RIMA anti-depressant.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1546136     DOI： 10.1007/bf02246230

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN： 0033-3158            Impact factor:   4.530


  7 in total

1.  Hepatic injury in patients who have received iproniazid.

Authors:  H POPPER
Journal:  Ann N Y Acad Sci       Date:  1959-09-17       Impact factor: 5.691

Review 2.  Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors.

Authors:  M Da Prada; R Kettler; H H Keller; W P Burkard; W E Haefely
Journal:  J Neural Transm Suppl       Date:  1989

3.  Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs.

Authors:  B Blackwell; E Marley; J Price; D Taylor
Journal:  Br J Psychiatry       Date:  1967-04       Impact factor: 9.319

4.  Tyramine pressor effect in man: studies with moclobemide, a novel, reversible monoamine oxidase inhibitor.

Authors:  A Korn; M Da Prada; W Raffesberg; S Allen; S Gasic
Journal:  J Neural Transm Suppl       Date:  1988

Review 5.  On tyramine, food, beverages and the reversible MAO inhibitor moclobemide.

Authors:  M Da Prada; G Zürcher; I Wüthrich; W E Haefely
Journal:  J Neural Transm Suppl       Date:  1988

6.  The lack of hepatotoxicity in the rat with the new and reversible MAO-A inhibitor moclobemide in contrast to iproniazid.

Authors:  B Schläppi
Journal:  Arzneimittelforschung       Date:  1985

7.  Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors.

Authors:  P R Bieck; K H Antonin
Journal:  J Neural Transm Suppl       Date:  1989
  7 in total
  2 in total

Review 1.  Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide.

Authors:  M Mayersohn; T W Guentert
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

Review 2.  A risk-benefit assessment of moclobemide in the treatment of depressive disorders.

Authors:  T R Norman; G D Burrows
Journal:  Drug Saf       Date:  1995-01       Impact factor: 5.606
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.